I wonder if a big fish like Accacia are interested in taking a strong position in nfx. Looking at its recent buy in to Synairgen I think why not. It has bucket loads of money to invest in life science entities and is actively scouring..
I think the £1m cash available from the Midcap draw down was from the £2m figure accessed already so probably £2m owed and not £3m as you say. I could well be wrong.
When we discussed capitalization earlier in the year I was genuinely disagreed with for suggesting a share consolidation. Mind you that was before we announced the Fundraise and the giant swelling of shares in Issue to come.
Consequently I am more persuaded that a rejig of shares will occur. 1 for 25 or even up to 1 for 100. The discount that way will be eased from focus. You may be right in your reference to poker, but I think someone lost sight of the company's worth in the orchestrated scramble
I agree with Wolfie that a much lower discount was the way to go .
Oh well head down and hope for better things to come
The fund raise seemed like a mad dash for cash at any price. A 75% discount to the closing price and a relatively modest capital sum targeted and raised begs the Qs why the substantial discount and why the limited target raised.
Would a company representative like to explain ; after all we were cashed up until August. Is anyone out there going to argue that it was the best that we could achieve? Factor in btw the new collaboration announced and the pretty stella FY Results.
I have a sizeable holding and want NFX to fly far higher, but I cannot agree rhetoric that fed up holders is a buy signal in itself.
It seems rather hollow IG.
News holds the key and there is an uncomfortable truth to be faced: ie there is a huge difference between a hot prospect and a hard sale, or put another way between hope of good news and confirmation that those hopes are achieved .
In my view super results and all the more cause to question the shot gun style very recent Raise squeezed into a few hours after close at a draconian discount. The price of 0.25p was shocking , the fundraise oversubscribed, and the capital raised, in my view quite limited. It is only mildly more than the Company's turnover.
I have no doubt that TRX is successful so why constrain and drain itself in such a bargain basement stampede.
Go figure and if you do let me know.
Perhaps one of those who engineered it might care to explain it. An explanation would be useful.
Transformational or Smoke& Mirrors04 Jun 2020 12:22
I am a LTH & I admit to being frustrated with NFX.
So I re read the 27May RNS and regained some enthusiasm.
Saliently it records:
That it is focused on completing a pan-Asia out licensing Agreement for NPX 002. It seems confident of securing this within the next few months.
A further payment from Ebers was triggered by the filing of a further Cannaboid Patent and collaboration continues.
It has not given up on the £2.5m China debt but acknowledges that enforcing it is not guaranteed. (is a pyrric victory worth it?). Meanwhile it is open to 3rd Party relicensing of global rights to NFX001 and to increased other application exposure to it
Its NFX 004 pilot study is expected to complete in the coming weeks notwithstanding the commandeering of NFRG staff to Milton Keynes and Government efforts. (Could the Milton Keynes exposure open up new possibilities for NFX I wonder)
Its new collaboration (anxiety and depression etc) with Vistagen was announced on the 27th May too.
Revenues from new and existing collaborations continue.